Are These 10 Sick Healthcare Companies Terminally Ill?
Savient (SVNT) is one I know well. Unfortunately, I added it prematurely to my Top 20 Model Portfolio earlier this year. I was and remain excited about their new CEO, who joined from Eli Lilly (LLY), where he had remained after it bought Imclone (he was the CEO). He has used his deep industry experience (formerly ran JNJ's biotech) to beef up management, which is focused on the launch of KRYSTEXXA, which treats gout. The problem for the company has been a slow launch due to the lack of a billing code, but this should be resolved later this year. The CEO took a lot of stock and has a special incentive to get the company sold. I think this one works well in 2012.